Zhitong Financial App News, Lee's Pharmaceutical Factory (00950.HK) announced that on July 6, 2026, the company signed an exclusive license agreement with Ashlins Ocular Pharmaceuticals, Inc. (Ashlins). Ashlins is an American biomedical company and a wholly-owned subsidiary of Ashlins Pharmaceuticals Holdings, Inc. focused on the acquisition, development and commercialization of clinically proven therapies in areas where there is a huge gap in medical demand. Under the agreement, the company agreed to license and supply interferon alpha-2b to Ashlins to develop and commercialize drugs for the diagnosis, prevention or treatment of certain human diseases in all regions other than mainland China, Hong Kong, Macau and Taiwan. The company will receive an advance payment and can receive additional development milestone payments based on specific achievements and annual commercialization milestone payments after commercialization.

Zhitong Financial App News, Lee's Pharmaceutical Factory (00950.HK) announced that on July 6, 2026, the company signed an exclusive license agreement with Ashlins Ocular Pharmaceuticals, Inc. (Ashlins). Ashlins is an American biomedical company and a wholly-owned subsidiary of Ashlins Pharmaceuticals Holdings, Inc. focused on the acquisition, development and commercialization of clinically proven therapies in areas where there is a huge gap in medical demand. Under the agreement, the company agreed to license and supply interferon alpha-2b to Ashlins to develop and commercialize drugs for the diagnosis, prevention or treatment of certain human diseases in all regions other than mainland China, Hong Kong, Macau and Taiwan. The company will receive an advance payment and can receive additional development milestone payments based on specific achievements and annual commercialization milestone payments after commercialization.